Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)

What Was Tested

This registered phase 2 trial tested Teduglutide (GLP-2 analog).

Environmental enteric dysfunction is a long-lasting condition of the small intestine.

It causes inflammation and poor absorption of nutrients.

It had 1 arm (groups): Teduglutide Treatment Arm (experimental).

The registry classes the interventions as drug.

More on the Plan

Knowledge gap: Currently, there is no available treatment for this condition.

However, teduglutide has not yet been trialed in adults with EED.

Methods: This is a community-based, single-arm, open-label, pilot intervention study.

Undernourished women aged 18-35 years with a Body Mass Index (BMI) between 16 to 18.5 kg/m² will be enrolled from Bauniabadh and adjacent slum areas in Mirpur, Dhaka.

Who Took Part

55 planned participants were the target.

It was open to women only aged from 18 years up to 35 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: BMI between 16 kg/m2 to 18.5 kg/m2. No antibiotics for 1 month. Willing to sign the consent form. Willing to receive food and multiple micronutrient supplementation for 2 months. Willing to receive daily one-month sub-cutaneous GLP 2 analog, Teduglutide treatment.

The full record lists 7 inclusion and 5 exclusion criteria; among the exclusions: pregnancy, lactation, drug abuse, known psychiatric disorders; known allergy to any components of nutrition intervention or any gi polyp; ongoing episode of diarrhea, history of persistent diarrhea in the past month or history of acute diarrhea in the past 7 days.

How the Study Was Run

It was run as a single-group and open-label study.

Everyone knew when Teduglutide (GLP-2 analog) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-07-01 with completion listed for 2027-10-01.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Composite EED (Environmental Enteric Dysfunction) Histopathologic Score (time frame: Baseline and 30 days after teduglutide treatment).

What This Means in Plain Language

Put simply, this is a phase 2 trial of Teduglutide (GLP-2 analog) in 55 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.